NASDAQ
ALNY

Alnylam Pharmaceuticals Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Alnylam Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$210.2026
Today's High:
$219.7700
Open Price:
$213.3100
52W Low:
$117.58
52W High:
$236.8
Prev. Close:
$213.1200
Volume:
663034

Company Statistics

Market Cap.:
$26.371 billion
Book Value:
1.455
Revenue TTM:
$0.961 billion
Operating Margin TTM:
-82.3%
Gross Profit TTM:
$0.704 billion
Gross Profit TTM:
$0.704 billion
Profit Margin:
-123%
Return on Assets TTM:
-14.1%
Return on Equity TTM:
-343.5%

Company Profile

Alnylam Pharmaceuticals Inc had its IPO on 2004-06-01 under the ticker symbol ALNY.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Alnylam Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Alnylam Pharmaceuticals Inc opened at $213.31 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $210.2 - $219.77, and closed at $214.35.

This is a +0.58% increase from the previous day's closing price.

A total volume of 663,034 shares were traded at the close of the day’s session.

In the last one week, shares of Alnylam Pharmaceuticals Inc have increased by +7.71%.

Alnylam Pharmaceuticals Inc's Key Ratios

Alnylam Pharmaceuticals Inc has a market cap of $26.371 billion, indicating a price to book ratio of 142.92 and a price to sales ratio of 27.44.

In the last 12-months Alnylam Pharmaceuticals Inc’s revenue was $0.961 billion with a gross profit of $0.704 billion and an EBITDA of $-0.749 billion. The EBITDA ratio measures Alnylam Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alnylam Pharmaceuticals Inc’s operating margin was -82.3% while its return on assets stood at -14.1% with a return of equity of -343.5%.

In Q3, Alnylam Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 40.9%.

Alnylam Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
-0.49

Its diluted EPS in the last 12-months stands at $-7.49 per share while it has a forward price to earnings multiple of - and a PEG multiple of -0.49. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alnylam Pharmaceuticals Inc’s profitability.

Alnylam Pharmaceuticals Inc stock is trading at a EV to sales ratio of 26.31 and a EV to EBITDA ratio of -27.03. Its price to sales ratio in the trailing 12-months stood at 27.44.

Alnylam Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Alnylam Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Alnylam Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Alnylam Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Alnylam Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Alnylam Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$214.35
52-Week High
$236.8
52-Week Low
$117.58
Analyst Target Price
$237.32

Alnylam Pharmaceuticals Inc stock is currently trading at $214.35 per share. It touched a 52-week high of $236.8 and a 52-week low of $236.8. Analysts tracking the stock have a 12-month average target price of $237.32.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Alnylam Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Alnylam Pharmaceuticals Inc is ALNY

The IPO of Alnylam Pharmaceuticals Inc took place on 2004-06-01

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$10.6
-0.25
-2.3%
$5.9
-0.16
-2.64%
$14.41
1.16
+8.75%
$24.5
-1.1
-4.3%
$21.75
-0.7
-3.12%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Address

675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, US